The short-term efficacy of the cyclooxygenase-2 selective inhibitor parecoxib was investigated for CRPS-induced pain and edema, but there was no difference in clinical outcomes compared with the placebo group (55). This evidence concerns the gene PTGS2 and complex regional pain syndrome.